Cocrystal Pharma, Inc.
COCP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $13 | $15 | $12 | $9 |
| Gross Profit | -$13 | -$15 | -$12 | -$9 |
| % Margin | – | – | – | – |
| R&D Expenses | $13 | $15 | $12 | $9 |
| G&A Expenses | $5 | $6 | $6 | $5 |
| SG&A Expenses | $5 | $6 | $6 | $5 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$13 | -$18 | $8 | -$9 |
| Operating Expenses | $5 | $3 | $26 | $5 |
| Operating Income | -$18 | -$19 | -$39 | -$14 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | $1 | -$0 | $0 |
| Pre-Tax Income | -$18 | -$18 | -$39 | -$14 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$18 | -$18 | -$39 | -$14 |
| % Margin | – | – | – | – |
| EPS | -1.72 | -0.002 | -4.77 | -1.85 |
| % Growth | -90,426.3% | 100% | -157.8% | – |
| EPS Diluted | -1.72 | -0.002 | -4.77 | -1.85 |
| Weighted Avg Shares Out | 10 | 10 | 8 | 8 |
| Weighted Avg Shares Out Dil | 10 | 10 | 8 | 8 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$18 | -$21 | -$18 | -$14 |
| % Margin | – | – | – | – |